Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile
Frontiers in Public Health · 2023
DOI: 10.3389/fpubh.2023.1229045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, 2023. Verfasst von Diego A Díaz-Dinamarca und 25 weiteren Autor:innen. Beteiligte Einrichtung: Sección de Biotecnología, Departamento Agencia Nacional de Dispositivos Médicos, Innovación y Desarrollo, Instituto de Salud Pública de Chile, Santia…. Hauptthemen laut MEDLINE: COVID-19, Vaccines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Severe acute respiratory syndrome virus 2 (SARS-CoV-2) has caused over million deaths worldwide, with more than 61,000 deaths in Chile. The Chilean government has implemented a vaccination program against SARS-CoV-2, with over 17.7 million people receiving a complete vaccination scheme. The final target is 18 million individuals. The most common vaccines used in Chile are CoronaVac (Sinovac) and BNT162b2 (Pfizer-Biotech). Given the global need for vaccine boosters to combat the impact of emerging virus variants, studying the immune response to SARS-CoV-2 is crucial. In this study, we characterize the humoral immune response in inoculated volunteers from Chile who received vaccination schemes consisting of two doses of CoronaVac [CoronaVac (2x)], two doses of CoronaVac plus one dose of BNT162b2 [CoronaVac (2x) + BNT162b2 (1x)], and three doses of BNT162b2 [BNT162b2 (3x)].
Methods
We recruited 469 participants from Clínica Dávila in Santiago and the Health Center Víctor Manuel Fernández in the city of Concepción, Chile. Additionally, we included participants who had recovered from COVID-19 but were not vaccinated (RCN). We analyzed antibodies, including anti-N, anti-S1-RBD, and neutralizing antibodies against SARS-CoV-2.
Results
We found that antibodies against the SARS-CoV-2 nucleoprotein were significantly higher in the CoronaVac (2x) and RCN groups compared to the CoronaVac (2x) + BNT162b2 (1x) or BNT162b2 (3x) groups. However, the CoronaVac (2x) + BNT162b2 (1x) and BNT162b2 (3x) groups exhibited a higher concentration of S1-RBD antibodies than the CoronaVac (2x) group and RCN group. There were no significant differences in S1-RBD antibody titers between the CoronaVac (2x) + BNT162b2 (1x) and BNT162b2 (3x) groups. Finally, the group immunized with BNT162b2 (3x) had higher levels of neutralizing antibodies compared to the RCN group, as well as the CoronaVac (2x) and CoronaVac (2x) + BNT162b2 (1x) groups.
Discussion
These findings suggest that vaccination induces the secretion of antibodies against SARS-CoV-2, and a booster dose of BNT162b2 is necessary to generate a protective immune response. In the current state of the pandemic, these data support the Ministry of Health of the Government of Chile’s decision to promote heterologous vaccination as they indicate that a significant portion of the Chilean population has neutralizing antibodies against SARS-CoV-2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sección de Biotecnología, Departamento Agencia Nacional de Dispositivos Médicos, Innovación y Desarrollo, Instituto de Salud Pública de Chile, Santiago, Chile.
- Sección gestión de la información, Departamento Agencia Nacional de Dispositivos Médicos, Innovación y Desarrollo, Instituto de Salud Pública de Chile, Santiago, Chile.
- Tecnología Medica, Facultad de Medicina, Clínica Alemana-Universidad del Desarrollo, Universidad del Desarrollo, Santiago, Chile.
- Departamento de Bioquímica Clínica e Inmunología, Facultad de Farmacia, Universidad de Concepción, Concepción, Chile.
- Unidad de investigación Clínica, Clínica Dávila, Santiago, Chile.
- Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Zitieren
APA
Díaz-Dinamarca, D. A., Díaz, P., Barra, G., Puentes, R., Arata, L., Grossolli, J., Riveros-Rodriguez, B., Ardiles, L., Santelises, J., Vasquez-Saez, V., Escobar, D. F., Soto, D., Canales, C., Díaz, J., Lamperti, L., Castillo, D., Urra, M., Zuñiga, F., Ormazabal, V., …, & Vasquez, A. E. (2023). Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2023.1229045
Vancouver
Díaz-Dinamarca DA, Díaz P, Barra G, Puentes R, Arata L, Grossolli J, et al. Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile. Frontiers in Public Health. 2023. doi:10.3389/fpubh.2023.1229045
BibTeX
@article{DazDinamarca2023,
author = {Díaz-Dinamarca, Diego A and Díaz, Pablo and Barra, Gisselle and Puentes, Rodrigo and Arata, Loredana and Grossolli, Jonnathan and Riveros-Rodriguez, Boris and Ardiles, Luis and Santelises, Julio and Vasquez-Saez, Valeria and Escobar, Daniel F and Soto, Daniel and Canales, Cecilia and Díaz, Janepsy and Lamperti, Liliana and Castillo, Daniela and Urra, Mychel and Zuñiga, Felipe and Ormazabal, Valeska and Nova-Lamperti, Estefanía and Benítez, Rosana and Rivera, Alejandra and Cortes, Claudia P and Valenzuela, María Teresa and García-Escorza, Heriberto E and Vasquez, Abel E},
title = {Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile},
journal = {Frontiers in Public Health},
year = {2023},
doi = {10.3389/fpubh.2023.1229045}
}
EUVIMED